Skip to content

Cumulative Live Birth Rates in Patients With Repeated Implantation Failure (RIF) Undergoing Preimplantation Genetic Screening (PGS )

Cumulative Live Birth Rates in Patients With Repeated Implantation Failure (RIF) Undergoing Preimplantation Genetic Screening (PGS )

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03001648
Enrollment
80
Registered
2016-12-23
Start date
2014-01-31
Completion date
2016-12-31
Last updated
2016-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Preimplantation Genetic Screening

Brief summary

This is a single centre retrospective study in repeated implantation failure patients: \< 39 years old, at least 4 D3 good quality embryos or 2 good quality blastocysts transferred without implantation, absence of known causes of implantation failures (uterine malformation, thrombophilia, severe male factor, uncontrolled thyroid disfunction, autoimmune disease). Patients scheduled for PGS underwent one or more stimulation cycles (oocyte or blastocyst banking) in order to maximize chances of embryo transfer. PGS cycles are analyzed globally. Aditionally, PGS cycles with a single stimulation cycle are analyzed in comparison to standard IVF cycles.

Interventions

PROCEDUREPGS (Preimplantation Genetic Screening) with trophectoderm biopsy

PGS (Preimplantation Genetic Screening) with trophectoderm biopsy using arrays comparative genomic hybridizatioon (aCGH)

Sponsors

Fundacion Dexeus
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 38 Years
Healthy volunteers
No

Inclusion criteria

* women \< 39 years * repeated implantation failure: at least 4 day 3 good quality embryos or 2 good quality blastocysts transferred without implantation

Exclusion criteria

* partner with severe male factor, or abnormal sperm Fluorescence in situ hybridization (FISH) analysis * presence of uni or bilateral hydrosalpinx, uterine malformation, thrombophilia, uncontrolled thyroid disfunction or autoimmune disease

Design outcomes

Primary

MeasureTime frame
Cumulative live birth rateat 24 months of first embryo transfer

Secondary

MeasureTime frame
Clinical Pregnancy Rate6 weeks after embryo transfer
Implantation Rate6 weeks after embryo transfer
Miscarriage RateUntil 20 weeks after embryo transfer

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026